Extracorporeal Membrane Oxygenation Machine Market by Modality (Venoarterial, Venovenous, and Arteriovenous), Application (Cardiac Applications, Respiratory Applications, and Extracorporeal Cardiopulmonary Resuscitation (ECPR)) and Geography: Global Market Size Estimates and Forecast (2022-2030)

Code: BMIRE00026018 | Pages: 100 | Industry: Medical Device | Date: Sep 2022 | Type: Global

The market crossed US$ 550 million mark in 2022 and is expected to hit US$ 700 million by 2030, recording a CAGR of 4.0% during the forecast period.

The extracorporeal membrane oxygenation (ECMO) machine market has been significantly growing with the number of lung transplantation procedures.  

The most frequent indication for the utilization of ECMO is Primary Graft Dysfunction (PGD) post lung transplantation. PGD is a disease containing lung injury during the first 72 hours after lung transplant. With important improvements in technologies, several studies have shown positive results related to the use of ECMO as a bridging strategy and therapy for patients suffering from PGD, post-transplant. The Portable ECMO machine segment is expected to hold the majority of the market during the forecast period as they can be transported to any anticipated location and are light in weight.

Within the report, the market is segmented into modality, application, and geography. By modality, the market is segmented into venoarterial, venovenous, and arteriovenous. Based on application, the market is segmented into cardiac applications, respiratory applications, and extracorporeal cardiopulmonary resuscitation. Geographically, the market is sub segmented into North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa.

Increasing survival rates with ECMO will provide future opportunity

Extracorporeal membrane oxygenation machines are medical devices that provide patients with cardiac and respiratory life support. Extracorporeal membrane oxygenation machine provides prolonged life support to the patients as their organs cannot perform their functions. Survival rates of ECMO patients depend on the underlying disease and the patient’s age. VV-ECMO is designated for patients with potentially reversible respiratory failure, such as those with severe acute respiratory distress syndrome (ADRS), primary graft dysfunction post a lung transplant, and trauma to the lungs. Utilizing VV-ECMO for respiratory failure patients increases their survival rates.

Rising patient awareness regarding the advantages of ECMO is one of the major factors accelerating market growth.

The increasing awareness among population regarding the importance of cardiopulmonary assistance for severe cardiac and respiratory conditions will boost the adoption rate of ECMO therapy. The introduction of patient awareness programs regarding ECMO devices and their application in emerging economies has resulted in a surge in their demand. For instance, the Latina Preventive Heart Disease (LPHD) program was introduced in Latin America to spread awareness regarding advanced therapies and instruments for CVD diseases. Such initiatives helped the ECMO industry to flourish in this region. 

Extracorporeal Membrane Oxygenation Machine Market

Get more information on this report :

Recent strategic developments in extracorporeal membrane oxygenation machine market

The extracorporeal membrane oxygenation machine market has undergone several significant developments, and a few of these have been mentioned below:

  • In July 2021, Xenios AG gained approval from the China National Medical Products Administration for the Xenios Console and patient kits for ECMO therapy.
  • In February 2020, Fresenius Medical care AG & Co. KGaA received US FDA clearance Novalung, a heart and lung support system for treating acute respiratory or cardiopulmonary failure.

Several players drive the extracorporeal membrane oxygenation machine market by implementing strategic activities such as investments, new launches, mergers & acquisitions, and partnerships. Getinge Group, Medtronic plc, Fresenius  Medicalcare AG & Co. KGAA, Microport, and Terumo Cardiovascular Systems Corporation are among the prominent players operating in the market.

The target audience for the report:

  • Drug developing companies
  • Contract development and manufacturing organization,
  • Drug discovery-related associations, organizations, forums, and alliances
  • Government bodies, such as regulating authorities and policymakers
  • Venture capitalists, private equity firms, and start-up companies
  • Drug distributors and sales firms
  • End users of drug discovery
  • Research institutes, organizations, and consulting companies

Scope of the report:

In this report, the market has been segmented on the basis of:

  • Modality:
    • Venoarterial
    • Venovenous
    • Arteriovenous
    • Stapler
  • Application:
    • Cardiac applications
    • Respiratory applications
    • Extracorporeal cardiopulmonary resuscitation (ECPR)
  • Region
    • North America
    • Europe
    • Asia Pacific (APAC)
    • South & Central America
    • Middle East & Africa
  • Companies profiled
    • MicroPort Scientific Corporation.
    • Medtronic
    • MAQUET Holding B.V. & Co. KG.
    • Getinge AB
    • TERUMO CORPORATION
    • NIPRO
    • ALung Technologies, Inc
    • EUROSETS
    • OriGen Biomedical
    • LivaNova PLC

Companies profiled
- MicroPort Scientific Corporation.
- Medtronic
- MAQUET Holding B.V. & Co. KG.
- Getinge AB
- TERUMO CORPORATION
- NIPRO
- ALung Technologies, Inc
- EUROSETS
- OriGen Biomedical
- LivaNova PLC


Report Code
Full Name
Country Name
Email Id
Phone Number
Job Title
Company
Requirement

Note : Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.


Purchase Options
Single User License
$1500
Site License
$2500
Enterprise License
$3500